Q&A: Genentech's new CEO on AI, IRA and radiopharma

Max Bayer

Pharma Reporter

Genentech and Roche are pretty much the only two companies that Ashley Magargee knows. The biopharma veteran has spent two decades at both (including before …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: Genentech's new CEO on AI, IRA and radiopharma

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Are programs with compounded GLP-1s safe for your population?

Q&A: Genen­tech's new CEO on AI, IRA and ra­dio­phar­ma

Max Bayer

Pharma Reporter

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Q&A: Genentech's new CEO on AI, IRA and radiopharma

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

NewAmsterdam aces Phase 3 trial, but investors are skeptical

FDA updates label of 33-year-old cancer drug with new dose and warning

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

Are programs with compounded GLP-1s safe for your population?